Chemotherapy and targeted therapy before surgery for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy and a targeted drug (fruquintinib) given before surgery to shrink colorectal cancer. It aims to see if this approach helps make tumors easier to remove or even disappear, especially for patients whose cancer has spread a little or is in a tricky spot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has been confirmed by a biopsy.
- Your cancer is either stage II, III, or stage IV that can still be removed with surgery, or it's initially too advanced to operate but might become removable after treatment.
- You have not had any prior cancer treatment (like chemotherapy, radiation, or immunotherapy) for this cancer (for the neoadjuvant group).
- You are willing and able to receive at least 2 cycles of fruquintinib plus chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a combination of two oral drugs (fruquintinib and camrelizumab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with advanced colorectal cancer that has spread to the liver. It's for those whose first treatment has stopped working and whose cancer is not the MSI-H type.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.